Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

PARAMESWA VENUGOPAL

Allopathic & Osteopathic Physicians Internal Medicine Hematology

NPI
1093774465
CMS profile
186187
Location
CHICAGO, IL

General Payments · PY2018–2024

$133,759.83

  • Reported across 101 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$38,824.67

31 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Genmab U.S., Inc. $12,403.69 11
ADC Therapeutics America, Inc. $12,374.29 9
BeiGene USA, Inc. $6,886.85 3
Ipsen Biopharmaceuticals, Inc $3,586.80 2
ABBVIE INC. $3,425.98 5
Janssen Scientific Affairs, LLC $147.06 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $15,078.57 25
PY2019 $9,124.04 7
PY2020 $12,015.00 4
PY2021 $3,488.94 4
PY2022 $26,439.83 19
PY2023 $28,788.78 11
PY2024 $38,824.67 31

Payment records · PY2024 (31)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
ABBVIE INC. $25.00 06/29/2024 Food and Beverage Undisputed 01/23/2026 1106279866 CMS
ABBVIE INC. $60.00 06/29/2024 Food and Beverage Undisputed 01/23/2026 1106279868 CMS
ABBVIE INC. $2,900.00 08/09/2024 Consulting Fee Undisputed 01/23/2026 1106279870 CMS
ABBVIE INC. $362.50 09/27/2024 Consulting Fee Undisputed 01/23/2026 1106279872 CMS
ABBVIE INC. $78.48 12/07/2024 Food and Beverage Undisputed 01/23/2026 1106279874 CMS
ADC Therapeutics America, Inc. $307.95 09/03/2024 Travel and Lodging Undisputed 01/23/2026 1121186880 CMS
ADC Therapeutics America, Inc. $322.94 09/20/2024 Travel and Lodging Undisputed 01/23/2026 1121186866 CMS
ADC Therapeutics America, Inc. $140.00 09/20/2024 Food and Beverage Undisputed 01/23/2026 1121186868 CMS
ADC Therapeutics America, Inc. $72.00 09/20/2024 Food and Beverage Undisputed 01/23/2026 1121186870 CMS
ADC Therapeutics America, Inc. $40.00 09/20/2024 Food and Beverage Undisputed 01/23/2026 1121186872 CMS
ADC Therapeutics America, Inc. $100.00 09/20/2024 Food and Beverage Undisputed 01/23/2026 1121186874 CMS
ADC Therapeutics America, Inc. $11,200.00 10/31/2024 Consulting Fee Undisputed 01/23/2026 1121186884 CMS
ADC Therapeutics America, Inc. $95.71 12/10/2024 Food and Beverage Undisputed 01/23/2026 1121186876 CMS
ADC Therapeutics America, Inc. $95.69 12/10/2024 Travel and Lodging Undisputed 01/23/2026 1121186878 CMS
BeiGene USA, Inc. $2,250.00 04/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1120855684 CMS
BeiGene USA, Inc. $136.85 12/03/2024 Food and Beverage Undisputed 01/23/2026 1120855680 CMS
BeiGene USA, Inc. $4,500.00 12/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1120855682 CMS
Genmab U.S., Inc. $6,312.80 07/16/2024 Travel and Lodging Undisputed 01/23/2026 1126830584 CMS
Genmab U.S., Inc. $240.00 07/19/2024 Travel and Lodging Undisputed 01/23/2026 1126830572 CMS
Genmab U.S., Inc. $17.42 07/19/2024 Food and Beverage Undisputed 01/23/2026 1126830580 CMS
Genmab U.S., Inc. $243.93 07/19/2024 Travel and Lodging Undisputed 01/23/2026 1126830582 CMS
Genmab U.S., Inc. $55.28 07/20/2024 Food and Beverage Undisputed 01/23/2026 1126830570 CMS
Genmab U.S., Inc. $17.41 07/20/2024 Food and Beverage Undisputed 01/23/2026 1126830574 CMS
Genmab U.S., Inc. $12.41 07/20/2024 Food and Beverage Undisputed 01/23/2026 1126830576 CMS
Genmab U.S., Inc. $243.75 07/20/2024 Travel and Lodging Undisputed 01/23/2026 1126830578 CMS
Genmab U.S., Inc. $12.41 07/20/2024 Food and Beverage Undisputed 01/23/2026 1126830586 CMS
Genmab U.S., Inc. $5,160.00 08/09/2024 Consulting Fee Undisputed 01/23/2026 1126830568 CMS
Genmab U.S., Inc. $88.28 09/05/2024 Food and Beverage Undisputed 01/23/2026 1126830566 CMS
Ipsen Biopharmaceuticals, Inc $3,480.00 09/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1091969235 CMS
Ipsen Biopharmaceuticals, Inc $106.80 09/12/2024 Food and Beverage Undisputed 01/23/2026 1091969237 CMS
Janssen Scientific Affairs, LLC $147.06 04/17/2024 Food and Beverage Undisputed 01/23/2026 1078849779 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.